CONFERENCE UPDATE: EADV 2022
Baricitinib as a potential therapeutic option for moderate-to-severe AD children
Dupilumab as the first and only drug gains FDA approval for treating EoE
Dupilumab, a monoclonal antibody previously indicated for the treatment of atopic dermatitis and asthma, has been recently approved by the United States (US) Food and Drug Administration (FDA) for treating eosinophilic esophagitis (EoE), a chronic, inflammatory disease in which the build-up of a typ
Baricitinib yields favorable outcomes in JIA: the phase 3 JUVE-BASIS trial